Victor Salazar Calderon, MD
Neurology · Phoenix, AZNPI 1508822974
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $183,719 of the $202,933 with a category attached, or 90.5%. AbbVie accounts for 86.8% of it on its own, with 19 other manufacturers making up the rest. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 533 payments — averaging $380.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$176K
- Axsome Therapeutics, Inc.$21K
- Medtronic$1K
- Acadia Pharmaceuticals Inc$648
- Inspire Medical Systems, Inc.$621
- UCB, Inc.$517
- plus $3K from 14 others
What the payments were for
- Speaking & faculty fees$183,71991%
- Travel & lodging$9,2275%
- Food & beverage$9,9785%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 378 | $176,059 |
| Axsome Therapeutics, Inc. | 15 | $21,290 |
| Medtronic(2 entities) | 18 | $1,206 |
| Acadia Pharmaceuticals Inc | 45 | $648 |
| Inspire Medical Systems, Inc. | 7 | $621 |
| UCB, Inc. | 35 | $517 |
| Eisai Inc. | 11 | $426 |
| Novo Nordisk | 4 | $421 |
| Amgen | 2 | $265 |
| Livanova USA, Inc. | 6 | $260 |
| AstraZeneca | 2 | $225 |
| Teva Pharmaceuticals USA, Inc. | 2 | $202 |
| Edwards Lifesciences | 1 | $161 |
| Madrigal Pharmaceuticals | 1 | $126 |
| Shire North American Group Inc | 1 | $116 |
| Abbott | 1 | $111 |
| Phathom Pharmaceuticals, Inc. | 1 | $107 |
| Angiodynamics, Inc. | 1 | $78 |
| Boston Scientific | 1 | $61 |
| Penumbra, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$202,933 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 148 | $244,974 |
| NuplazidPimavanserin Tartrate | 30 | $177,770 |
| BriviactBrivaracetam | 87 | $140,194 |
| QuliptaAtogepant | 52 | $62,355 |
| UbrelvyUbrogepant | 36 | $62,310 |
| FycompaPerampanel | 37 | $40,039 |
| NeuproRotigotine | 32 | $29,896 |
| Divalproex Sodium ErDivalproex Sodium | 160 | $19,472 |
| Emgality PenGalcanezumab-Gnlm | 11 | $11,921 |
| Rasagiline Mesylate | 36 | $9,605 |
| Carbamazepine ErCarbamazepine | 51 | $9,144 |
| Levetiracetam | 196 | $8,417 |
| LyricaPregabalin | 13 | $8,277 |
| Rivastigmine | 18 | $6,225 |
| Galantamine Hbr | 33 | $6,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric, Qulipta, Ubrelvy | $176,059 | $369,640236 claims |
| Acadia Pharmaceuticals IncNuplazid | $648 | $177,77030 claims |
| UCB, Inc.Briviact, Neupro | $517 | $170,090119 claims |
| Eisai Inc.Fycompa | $426 | $40,03937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.